Image Place holder

Nainesh Parikh, MD, MBA

Specialty: Interventional Radiology
Program: Diagnostic Imaging and Interventional Radiology

Call 1-888-MOFFITT

Call 1-888-MOFFITT

Locations: Moffitt Cancer Center

Cancer Focus: Bladder Cancer , Head and Neck Cancer , Kidney (Renal Cell) Cancer , Liver Cancer , Oral Cavity or Throat Cancer , Penile Cancer, Prostate Cancer , Testicular Cancer , Throat Cancer, Tongue Cancer

Dr. Parikh’s clinical interests include treating patients with advanced malignancy utilizing minimally invasive techniques. Specific areas of interest include liver directed therapy for primary and secondary liver cancer, as well as for primary kidney cancer. Additionally, Dr. Parikh is interested in treating malignant and non-malignant tumors within the GU system, such as prostate cancer and benign prostatic hyperplasia, respectively. Dr. Parikh earned his undergraduate degree from Columbia University in New York City, and subsequently worked as an investment banker after graduation. After deciding that he wanted to have a significant impact on the daily lives of patients, he obtained MD and MBA degrees from Tufts University School of Medicine in Boston, MA. He then completed diagnostic radiology residency at NYU Medical Center in New York City, before moving back to Boston to complete a fellowship in Angiography and Interventional Radiology at the Brigham and Women’s Hospital – Harvard Medical School.

Education & Training

Board Certification:

  • Diagnostic Radiology
  • Vascular & Interventional Radiology


  • NYU Medical Center - Body MR
  • Brigham and Women's Hospital/Harvard Medical School - Angiography and Interventional Radiology


  • NYU Medical Center - Diagnostic Radiology

Medical School:

  • Tufts University School of Medicine(MD/MBA, - MD/MBA)
Participating Trials

Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine plus Nab-Paclitaxel following Induction with sequential IV Gemcitabine plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer
Condition: Gastrointestinal Tumor
Intervention: Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); Xeloda (capecitabine); capecitabine (); gemcitabine ()

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.


  • Sweeney J, Parikh N, El-Haddad G, Kis B. Ablation of Intrahepatic Cholangiocarcinoma. Semin Intervent Radiol. 2019 Oct.36(4):298-302. Pubmedid: 31680720. Pmcid: PMC6823041.
  • Gunn AJ, Parikh NS, Bhatia S. Society of Interventional Radiology Quality Improvement Standards on Percutaneous Ablation in Renal Cell Carcinoma. J Vasc Interv Radiol. 2019 Dec.31(2):195-201.e3. Pubmedid: 31917026.
  • Gangi A, Shah J, Hatfield N, Smith J, Sweeney J, Choi J, El-Haddad G, Biebel B, Parikh N, Arslan B, Hoffe SE, Frakes JM, Springett GM, Anaya DA, Malafa M, Chen DT, Chen Y, Kim RD, Shridhar R, Kis B. Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study. J Vasc Interv Radiol. 2018 Aug;29(8):1101-1108. Pubmedid: 30042074.
  • Sweeney J, Parikh N. Inferior vena cava filter placement in a left IVC and drainage into duplicated SVC via hemiazygous continuation. Radiol Case Rep. 2018 Apr.13(2):320-323. Pubmedid: 29904464. Pmcid: PMC5999865.
  • Ream JM, Doshi AM, Dunst D, Parikh N, Kong MX, Babb JS, Taneja SS, Rosenkrantz AB. Dynamic contrast-enhanced MRI of the prostate: An intraindividual assessment of the effect of temporal resolution on qualitative detection and quantitative analysis of histopathologically proven prostate cancer. J Magn Reson Imaging. 2017 May;45(5):1464-1475. Pubmedid: 27649481. Pmcid: PMC5538355.
  • Kis B, El-Haddad G, Sheth RA, Parikh NS, Ganguli S, Shyn PB, Choi J, Brown KT. Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control. 2017 Jul.24(3). Pubmedid: 28975829. Pmcid: PMC5937250.
  • Rosenkrantz AB, Parikh N, Kierans AS, Kong MX, Babb JS, Taneja SS, Ream JM. Prostate Cancer Detection Using Computed Very High b-value Diffusion-weighted Imaging: How High Should We Go?. Acad Radiol. 2016 Jun;23(6):704-711. Pubmedid: 26992738.
  • Parikh N, Ream JM, Zhang HC, Block KT, Chandarana H, Rosenkrantz AB. Performance of simultaneous high temporal resolution quantitative perfusion imaging of bladder tumors and conventional multi-phase urography using a novel free-breathing continuously acquired radial compressed-sensing MRI sequence. Magn Reson Imaging. 2016 Jun;34(5):694-698. Pubmedid: 26740058. Pmcid: PMC4896486.
  • Navi BB, Parikh NS, Lerario MP, Merkler AE, Lappin RI, Fahimi J, Iadecola C, Kamel H. Risk of Intracerebral Hemorrhage after Emergency Department Discharges for Hypertension. J Stroke Cerebrovasc Dis. 2016 Jul;25(7):1683-1687. Pubmedid: 27068776. Pmcid: PMC4912410.
  • Parikh NS, Cool J, Karas MG, Boehme AK, Kamel H. Stroke Risk and Mortality in Patients With Ventricular Assist Devices. Stroke. 2016 11;47(11):2702-2706. Pubmedid: 27650070. Pmcid: PMC5079813.
  • Kierans A, Parikh N, Chandarana H. Recent Advances in MR Hardware and Software. Radiol Clin North Am. 2015 May;53(3):599-610. Pubmedid: 25953292.
  • Gaing B, Sigmund EE, Huang WC, Babb JS, Parikh NS, Stoffel D, Chandarana H. Subtype differentiation of renal tumors using voxel-based histogram analysis of intravoxel incoherent motion parameters. Invest Radiol. 2015 Mar;50(3):144-152. Pubmedid: 25387050.
  • Parikh N, Friedman KP, Shah SN, Chandarana H. Practical guide for implementing hybrid PET/MR clinical service: lessons learned from our experience. Abdom Imaging. 2015 Aug;40(6):1366-1373. Pubmedid: 25985966. Pmcid: PMC4534342.
  • Parikh N, Morris E, Babb J, Wickstrom M, McMenamy J, Sharma R, Schwartz D, Lifshitz M, Kim D. MDCT diagnosis of acute pulmonary embolism in the emergent setting. Emerg Radiol. 2015 Aug;22(4):379-384. Pubmedid: 25573686.